Photo from wikipedia
Key Points • Treatment with IL-15 before alemtuzumab was safe and led to decreased number and proliferative activity of T-cell leukemic cells.• IL-15 was associated with increased activation and proliferation… Click to show full abstract
Key Points • Treatment with IL-15 before alemtuzumab was safe and led to decreased number and proliferative activity of T-cell leukemic cells.• IL-15 was associated with increased activation and proliferation of patient-derived NK and CD8+ T cells, increasing their ADCC capacity.
Keywords:
cell;
mediated adcc;
augments cell;
interleukin augments;
alemtuzumab;
cell mediated
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!